Upstream Bio Reports $1M Collaboration Revenue, $40.6M Net Loss in Q1 2026

Upstream Bio, Inc. reported its financial results for the first quarter of 2026, revealing a collaboration revenue of $1.0 million, a significant increase from $566,000 in the same period last year. The rise in revenue is attributed to ongoing work related to the Phase 2 clinical trials for its lead product, verekitug, which targets severe respiratory disorders. Despite this revenue growth, the company incurred a net loss of $40.6 million for the quarter, compared to a net loss of $27.3 million in the first quarter of 2025, reflecting an increase in operating expenses primarily driven by research and development activities.

Total operating expenses for the first quarter of 2026 reached $44.6 million, up from $32.6 million in the prior year, marking a 37% increase. This rise is largely due to heightened research and development costs, which amounted to $36.6 million, compared to $25.8 million in the previous year. The increase in R&D expenses was primarily driven by costs associated with the ongoing clinical trials for verekitug, particularly for the chronic obstructive pulmonary disease (COPD) indication, which saw a notable increase in spending. General and administrative expenses also rose to $8.1 million from $6.8 million, reflecting higher personnel costs and professional fees.

As of March 31, 2026, Upstream Bio reported total assets of $318.1 million, a decrease from $353.8 million at the end of 2025. The decline in assets was primarily due to a reduction in short-term investments, which fell to $197.9 million from $239.9 million. The company’s cash and cash equivalents stood at $96.7 million, down from $101.6 million at the end of the previous fiscal year. The accumulated deficit increased to $374.8 million, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in its clinical programs.

In terms of operational developments, Upstream Bio is advancing its clinical trials for verekitug, with positive results reported in recent Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The company plans to initiate Phase 3 trials for both severe asthma and CRSwNP in early 2027. Upstream Bio has also expanded its workforce, which is reflected in the increased personnel expenses, and continues to seek additional financing to support its operations and growth strategy.

Looking ahead, Upstream Bio anticipates continued net operating losses as it progresses through its clinical trials and seeks regulatory approvals for verekitug. The company expects its existing cash and short-term investments will be sufficient to fund operations through 2027, but acknowledges the need for additional financing to support ongoing research and development efforts. The company remains focused on maximizing the potential of verekitug to address unmet medical needs in inflammatory diseases.